Opinion
-
Pharmacy benefit managers inflate drug prices and decrease competition while consumers pay the price. Does the FTC have the medicine to fix it?
Many have never heard of a pharmacy benefit manager, mega-profitable companies that control what consumers pay for prescription drugs. The FTC’s new probe needs to go far to change the status quo.
-
Why Texas wants to be the headquarters of ARPA-H
Texas has the right environment to help ARPA-H achieve its promise of eliminating existing deficiencies in our national biomedical ecosystem, promoting the integration of multiple disciplines and institutions, and fully addressing persistent inequities in America’s health system.
-
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
-
An audiologist’s take on the news that OTC hearing aids are on their way to consumers
If FDA’s decision on making hearing aids available over the counter leads to greater adoption, it could encourage consumers to learn more about their condition, and therefore improve the health literacy of the public. The downstream effect of this is to increase the perceived value of the audiologist beyond mere salespeople of a medical device, which audiologists everywhere should applaud.
-
MedCity Influencers, Health Services, Opinion
Patients will bear the steepest consequences of proposed cuts to home health
In the current market where inflation and the costs of healthcare continue to rise, there’s […]
-
Aduhelm’s loss is a win for value-based drug pricing
Value-based pricing could have shown us with more certainty the real level of effectiveness of Aduhelm. Maybe it is worth paying something for; and value-based contracts are the only way to figure that out.
-
Worried about long Covid? Support primate research
Nonhuman primates will be critical to our efforts to understand the long-term effects of Covid-19. Yet scientists conducting critical research have faced harassment and threats.
-
MedCity Influencers, Devices & Diagnostics, Opinion
Coverage delays exacerbate inequity for Medicare beneficiaries
Without reimbursement policies that can meet the opportunity of this new innovative era, patients and their providers will be denied access to the most cutting-edge, care.
-
MedCity Influencers, Opinion, Health Tech
Diabetes care needs to support lifestyle changes – not pharmaceutical intervention – first
While pharmaceuticals are a critical piece of the treatment landscape for type 2 diabetes, they have been the exclusive and de-facto first-line treatment for too long. Prescription digital therapeutics can and should be considered as part of type 2 diabetes therapies.
-
MedCity Influencers, BioPharma, Opinion
Is the HIF-PHI class of next-generation kidney drugs doomed in the U.S.?
Kidney disease patients need access to innovative therapies to expand treatment choices and improve quality of life. The FDA should closely examine whether it is applying the appropriate benefit/risk assessment for new drugs intended for this population.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
MedCity Influencers, Consumer / Employer
Meeting the quadruple aim through whole-person care
Covid-19 exposed how unhealthy we are as a nation making the case for whole-person care even stronger. All we need now is to focus on redesigning our health care system to deliver this type of care—and muster the courage to do it.
-
MedCity Influencers, Opinion, BioPharma
Lowering insulin prices isn’t the (only) answer to helping patients with diabetes
It is time to shift the conversation, incentives, and policy solutions to help people improve their health and get off of medications—not just make them cheaper.
-
MedCity Influencers, BioPharma, Opinion
Monoclonal antibodies are the way out of the Covid-19 pandemic
Whether they are acting as a therapeutic or preventive treatment, monoclonal antibodies can allow us to help contain the virus, where we might see the light at the end of the tunnel.
-
Direct-to-Consumer medical testing is something all medical labs should embrace
As more patients request direct-to-consumer (DTC) lab tests, medical laboratories will need to reconfigure and upgrade key aspects of their business in order to serve these new healthcare consumers properly. No longer a pure business-to-business endeavor, labs are now finding themselves in the consumer market.
-
Exceptionalism—A core problem in healthcare leadership
We believe that healthcare leadership’s ingrained culture of exceptionalism drives today’s profound problem whereby patient satisfaction is low, inefficiency is high, and patient outcomes are poor.
-
Free market is at risk because of PBM titans’ anti-competitive behaviors
Congress must thoroughly investigate the anti-competitive behaviors of these conglomerates and act accordingly. Doing so will provide better outcomes both for patients and a more competitive marketplace for unaffiliated pharmacies.
Promoted
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
